Table 4.
Number of strains | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
do not showing any resistance | resistant to one drug only | with multidrug resistancea | displayed resistance against | ||||||||||
ampicillin (MIC≥2 or 4 or 8 μg/ml) | tetracycline (MIC≥8 or 16 or 32 μg/ml) | erythromycin (MIC≥2 μg/ml) | lincomycin (MIC≥64 μg/ml) | streptomycin (MIC≥32 or 128 μg/ml) | gentamycin (MIC≥32 μg/ml) | chloramphenicol (MIC≥8 μg/ml) | enrofloxacin (MIC≥64 μg/ml) | erythromycin and lincomycin | streptomycin and gentamycin | ||||
L. salivarius
(n=22) |
0 | 2 (9%) |
15 (68%) |
10 (45%) |
13 (59%) |
9 (41%) |
14 (64%) |
11 (50%) |
1 (4.5%) |
9 (41%) |
20 (91%) |
9 (41%) |
1 (4.5%) |
L. agilis
(n=2) |
0 | 0 | 2 (100%) |
0 | 2 (100%) |
1 (50%) |
1 (50%) |
2 (100%) |
0 | 0 | 1 (50%) |
1 (50%) |
0 |
L. saerimneri
(n=3) |
0 | 0 | 1 (67%) |
3 (100%) |
0 | 0 | 0 | 3 (100%) |
3 (100%) |
1 (33%) |
0 | 0 | 3 (100%) |
L. johnsoni
(n=6) |
0 | 1 (17%) |
3 (50%) |
1 (17%) |
5 (83%) |
2 (33%) |
5 (83%) |
0 | 0 | 1 (17%) |
2 (33%) |
1 (17%) |
0 |
L. crispatus
(n=13) |
0 | 0 | 10 (77%) |
9 (69%) |
11 (85%) |
7 (54%) |
8 (61.5%) |
3 (23%) |
2 (15%) |
1 (8%) |
13 (100%) |
7 (38%) |
0 |
L. oris
(n=5) |
0 | 1 (20%) |
4 (80%) |
4 (80%) |
4 (80%) |
4 (80%) |
5 (100%) |
0 | 0 | 1 (20%) |
1 (20%) |
4 (80%) |
0 |
L. ingluviei
(n=9) |
3 (33%) |
0 | 5 (55.5%) |
2 (22%) |
6 (67%) |
5 (55.5%) |
5 (55.5%) |
0 | 0 | 5 (55.5%) |
0 | 5 (55.5%) |
0 |
L. reuteri
(n=2) |
0 | 1 (50%) |
0 | 0 | 1 (50%) |
0 | 2 (100%) |
0 | 0 | 0 | 0 | 0 | 0 |
Total: 62 |
3
(5%) |
5
(8%) |
40
(64.5%) |
29
(47%) |
42
(68%) |
28
(45%) |
40
(64.5%) |
19
(31%) |
6
(10%) |
18
(29%) |
37
(60%) |
27
(43.5%) |
4
(6%) |
aresistant to at least 3 groups of antimicrobial agents (the analysis excluded tiamulin, cephalothin, cefuroxime and ceftiofur for which the breakpoints has not been established)